Lixisenatide

Mechanism (as reported)

Mechanistic summaries in the provided sources describe GLP-1 receptor agonists (including short-acting agents such as lixisenatide) as increasing hyperglycemia-induced insulin secretion, suppressing glucagon secretion (at hyper- or euglycemia), and slowing gastric emptying; additional described class effects include reduction of calorie intake and body weight. Short-acting GLP-1RAs (including lixisenatide) are described as primarily lowering postprandial blood glucose through inhibition of gastric emptying.

Key findings (each cites a source)

• A state-of-the-art review described GLP-1 receptor agonists as being used for type 2 diabetes with regimens that include once-daily dosing with lixisenatide (contrasted with twice-daily exenatide and once-weekly GLP-1RAs). [PMID 33068776]
• The provided sources described shared GLP-1 receptor agonist class mechanisms as including augmentation of hyperglycemia-induced insulin secretion, suppression of glucagon secretion at hyper- or euglycemia, deceleration of gastric emptying, and reduction in calorie intake/body weight. [PMID 33068776]
• A review of individualized treatment described GLP-1 biology and reported that short-acting GLP-1 receptor agonists (including lixisenatide) primarily lower postprandial blood glucose through inhibition of gastric emptying. [PMID 22945360]
• A phase 2, double-blind, randomized, placebo-controlled trial (LIXIPARK) reported that lixisenatide led to less progression of motor disability than placebo at 12 months in participants with early Parkinson’s disease, using the MDS-UPDRS part III as the primary end point; the same report noted gastrointestinal side effects (nausea and vomiting) and that longer/larger trials are needed. [PMID 38598572]
• A randomized trial in type 2 diabetes with recent acute coronary syndrome (ELIXA) reported that adding lixisenatide to usual care showed noninferiority to placebo for a composite cardiovascular end point (cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina) but did not show superiority; it also reported no significant between-group differences in hospitalization for heart failure or death and no higher rates of several serious adverse outcomes compared with placebo. [PMID 26630143]
• An obesity review stated that GLP-1 agonists (class) have been shown to be effective in promoting weight loss and summarized effects including improving hyperglycemia, insulin sensitivity, blood pressure, cardio-metabolic and renal protection outcomes based on studies it reviewed. [PMID 37445623]
• A breastfeeding-focused source stated there is no information available on clinical use of lixisenatide during breastfeeding and suggested that because lixisenatide is a large peptide molecule, the amount in milk is likely to be very low and absorption is unlikely; it advised caution until more data are available, especially with newborns or preterm infants. [PMID 30000034]